PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Both companies show declining cash positions (-27.41% vs AVXL's -9.66%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Cash + STI yoy ≥ 1.5x AVXL's -9.66%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-28.37%
≥ 1.5x AVXL's -9.16%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
1187.39%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of AVXL's -100.00%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
252.00%
Below half of AVXL's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
≥ 1.5x AVXL's -9.36%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-8.53%
Less than half of AVXL's 64.99%. David Dodd sees a more disciplined AP approach or lower volume.
-29.62%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
12.29%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Less than half of AVXL's 25.52%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.42%
50-75% of AVXL's 25.52%. Bruce Berkowitz notes a lower yoy liability increase.
2.97%
1.25-1.5x AVXL's 2.07%. Martin Whitman sees potential dilution risk vs. competitor approach.
-3.03%
Below half AVXL's -6.73%. Michael Burry suspects major net losses or high dividends vs. competitor.
25.83%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
≥ 1.5x AVXL's -15.97%. David Dodd sees stronger capital base growth than competitor.
-17.83%
≥ 1.5x AVXL's -9.36%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
37.73%
Above 1.5x AVXL's 9.66%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.